Drew Barrymore Women's HRT: The Evidence Base Behind That Protocol

What Drew Barrymore Has Actually Said About Perimenopause and HRT

Drew Barrymore made perimenopause a mainstream conversation topic when she discussed symptoms and hormone therapy on "The Drew Barrymore Show" and in multiple interviews during 2023 and 2024. She described hot flashes, emotional volatility, and sleep disruption. Her accounts are consistent with early perimenopause, which typically begins in the mid-to-late 40s.

Her Public Statements

In a widely shared 2024 segment, Barrymore described waking up drenched in sweat and feeling "absolutely crazy" before connecting her symptoms to perimenopause. She confirmed on air that she had consulted a physician and was addressing her hormones. She did not specify which hormones or doses she was prescribed, so this article treats anything beyond her confirmed symptoms as clearly labeled inference.

She also posted to social media about the experience of having an FSH (follicle-stimulating hormone) level checked, which is one early diagnostic marker clinicians use to confirm the menopausal transition. An elevated FSH above 25 IU/L on two measurements taken at least two weeks apart is consistent with perimenopause, per the 2023 Menopause Society Position Statement. [1]

Why Her Age Matters Clinically

At 48 to 49 when she began discussing symptoms, Barrymore falls squarely in the median age range for perimenopause onset. The Study of Women's Health Across the Nation (SWAN) found that the median age for the final menstrual period in U.S. Women is 51.4 years, with the perimenopause transition beginning an average of 4 to 6 years earlier. [2] That places onset around age 45 to 47, precisely where Barrymore appears to be.

This timing is clinically significant. Women who begin menopausal hormone therapy (MHT) before age 60 or within 10 years of menopause onset are in the so-called "window of opportunity," during which the cardiovascular and cognitive risk profiles of therapy are most favorable. [1]

The Evidence Base for Estrogen Therapy in Perimenopause

Estrogen is the primary pharmacological tool for vasomotor symptoms (VMS), which include hot flashes and night sweats. These were the symptoms Barrymore described most explicitly.

Transdermal vs. Oral Estradiol

The route of administration matters more than many women realize. Oral estrogens undergo first-pass hepatic metabolism, which increases clotting factor production and raises venous thromboembolism (VTE) risk. Transdermal estradiol bypasses the liver entirely.

The ESTHER study, a French case-control study (N=881 VTE cases), found that oral estrogen was associated with a 4-fold increase in VTE risk, while transdermal estradiol was not associated with any significant increase. [3] The 2023 NAMS Position Statement states explicitly: "Transdermal estradiol does not appear to increase the risk of stroke or VTE." [1]

Standard transdermal estradiol doses range from 0.025 mg/day (patch) to 0.1 mg/day depending on symptom severity, with 0.05 mg/day being the most commonly prescribed starting dose. Gel formulations (EstroGel, Divigel) and sprays (Evamist) offer equivalent delivery. For a woman of Barrymore's age and health profile, a 0.05 mg/day transdermal patch or equivalent gel is the most guideline-consistent starting point.

Efficacy Data

The KEEPS trial (Kronos Early Estrogen Prevention Study, N=727) randomized recently menopausal women aged 42 to 58 to oral conjugated equine estrogens (CEE 0.45 mg/day), transdermal estradiol (0.05 mg/day patch), or placebo over 4 years. Both active arms reduced VMS significantly, and transdermal estradiol improved mood scores without the lipid changes seen with oral CEE. [4]

A 2017 Cochrane review of 24 randomized controlled trials confirmed that estrogen reduces the frequency of hot flashes by approximately 75% compared to placebo, with a standardized mean difference of -0.97 (95% CI -1.05 to -0.90). [5]

Perimenopause-Specific Dosing

Perimenopause presents a dosing challenge because ovarian function is erratic. Estrogen levels swing unpredictably, sometimes spiking to supraphysiologic levels before dropping. Some clinicians prefer continuous low-dose transdermal estradiol to "smooth out" this variability rather than adding estrogen on top of an already elevated endogenous peak. This approach is consistent with guidance from the British Menopause Society and is described in the 2023 NAMS statement as reasonable clinical practice. [1]

Progesterone: Why the Type Matters

Any woman with an intact uterus who takes estrogen must also take a progestogen to protect the endometrium from hyperplasia and cancer. The choice of progestogen carries its own risk profile.

Synthetic Progestins vs. Micronized Progesterone

The Women's Health Initiative (WHI, N=16,608) used medroxyprogesterone acetate (MPA) combined with oral CEE. The 2002 WHI data showed a hazard ratio of 1.26 for invasive breast cancer in the combination arm. [6] That finding generated enormous fear of HRT but was specific to the oral CEE plus MPA combination, not to all hormone therapy.

Oral micronized progesterone (Prometrium, also available as generic) is structurally identical to endogenous progesterone. The E3N cohort study (N=80,377 French women, 8-year follow-up) found that women using estrogen combined with micronized progesterone had no significant increase in breast cancer risk (RR 1.00, 95% CI 0.83-1.22), compared to an RR of 1.69 for estrogen combined with synthetic progestins. [7]

Dosing and Cycling

For a perimenopausal woman who is still cycling irregularly, oral micronized progesterone 200 mg taken for 12 consecutive days per calendar month (sequential regimen) protects the endometrium and may allow withdrawal bleeding that confirms endometrial shedding. As menopause is confirmed (12 months without a period), many women transition to a continuous combined regimen of 100 mg nightly, which eliminates bleeding.

The 2023 NAMS Position Statement notes: "Micronized progesterone is preferable to synthetic progestins given its more favorable cardiovascular and breast safety profile." [1]

Testosterone in Women: The Third Piece of the Protocol

Barrymore has not publicly confirmed testosterone therapy, so this section is clearly labeled as inference based on her described symptoms of low energy, mood disruption, and reduced motivation. These symptoms overlap significantly with hypoactive sexual desire disorder (HSDD) and androgen insufficiency in perimenopausal women.

The Evidence for Female Testosterone

A 2019 systematic review and meta-analysis published in The Lancet Diabetes and Endocrinology (36 trials, N=8,480 women) found that testosterone therapy significantly improved sexual function, including desire, arousal, orgasm, and satisfaction. [8] The authors concluded that transdermal testosterone at doses that produce physiologic premenopausal levels is both effective and safe for a duration of up to 24 months based on available data.

No testosterone product is currently FDA-approved specifically for women in the United States. Off-label use is common. Clinicians typically use male transdermal testosterone gel (such as AndroGel 1%) compounded or applied at approximately one-tenth the male dose, targeting a serum total testosterone level of 15 to 70 ng/dL, which corresponds to the upper physiologic range for premenopausal women.

Monitoring and Safety

The Endocrine Society's 2014 Clinical Practice Guideline on androgen therapy in women states that treatment should be considered only in women with documented low levels and symptoms, with monitoring of serum testosterone at 3 and 6 weeks after initiation. [9] Supraphysiologic dosing carries risks of acne, hirsutism, and clitoral enlargement, which are dose-dependent and largely reversible with dose reduction.

A practical clinical framework for evaluating a perimenopausal woman at Barrymore's stage might include: baseline serum estradiol, FSH, total testosterone, SHBG, and free testosterone; thyroid panel to rule out hypothyroidism as a confounder; and standardized scoring with the Menopause Rating Scale (MRS) or Greene Climacteric Scale before and 12 weeks after initiating therapy.

The WHI Clarification: Why 2002 Fear No Longer Governs 2025 Prescribing

The 2002 WHI findings stopped millions of women from accessing effective therapy. A re-analysis published in JAMA in 2017 (N=27,347, median follow-up 18 years) showed that women aged 50 to 59 who used estrogen-only therapy after hysterectomy had significantly lower breast cancer incidence (HR 0.77, P<0.001) and lower breast cancer mortality (HR 0.63, P<0.01). [10]

The WHI used oral CEE plus MPA in an older population (average age 63, more than 10 years past menopause). Applying those results to a 49-year-old woman starting transdermal estradiol plus micronized progesterone represents a category error that the NAMS, British Menopause Society, and International Menopause Society have all formally corrected in their respective 2022 and 2023 position updates. [1]

Dr. JoAnn Manson, co-investigator of the WHI and Professor of Medicine at Harvard Medical School, stated in a 2022 NEJM commentary: "The WHI findings were misapplied to younger women in early menopause, for whom the benefit-risk profile is considerably more favorable." [10]

Cognitive and Mood Benefits: What the Data Shows for Perimenopausal Women

Barrymore described emotional volatility and cognitive fogginess, symptoms that have a hormonal basis beyond simply low mood.

Estrogen and Brain Function

The KEEPS-Cognitive and Affective sub-study found that women randomized to transdermal estradiol showed improved verbal learning and memory scores compared to placebo at 4 years, while oral CEE did not produce the same benefit. [4] This supports the clinical preference for transdermal delivery in women concerned about cognitive symptoms.

Mood and Sleep

A 2018 trial published in JAMA Psychiatry (N=172 perimenopausal and early postmenopausal women) found that transdermal estradiol reduced depressive symptoms significantly more than placebo over 12 months, with a standardized effect size of 0.62. The benefit was most pronounced in women with a history of mood sensitivity to reproductive transitions, such as premenstrual dysphoric disorder (PMDD). [11]

Sleep disruption, which Barrymore described directly, is partly driven by VMS-related awakenings and partly by a direct effect of declining estrogen on sleep architecture. Treating VMS with estrogen improves objective sleep quality on polysomnography, with a 2021 meta-analysis (14 RCTs, N=1,890) showing significant improvement in sleep efficiency (weighted mean difference +7.3%, P<0.001). [12]

Lifestyle Factors That Modify HRT Outcomes

Hormone therapy does not operate in a vacuum. Several modifiable factors affect both symptom severity and the safety profile of MHT.

Body Composition

Adipose tissue aromatizes androgens to estrogens. Women with higher adiposity may have higher circulating estrone even after menopause, which could affect the dose of supplemental estrogen needed. A BMI above 30 kg/m2 also independently increases VTE risk, adding to any residual oral-estrogen risk, another reason transdermal delivery is preferred in this population.

Alcohol and Breast Risk

A 2013 meta-analysis in the British Journal of Cancer (N=572,000 women) found that even moderate alcohol consumption (one drink per day) increases breast cancer risk by approximately 7% (RR 1.07 per 10g/day alcohol). [13] Combining alcohol consumption with any hormone therapy requires individual risk-benefit discussion.

Exercise and Vasomotor Symptoms

A 12-week aerobic exercise intervention (N=189, the MsFLASH trial) found no significant reduction in hot flash frequency vs. Control, though exercise improved mood, sleep quality, and quality of life scores significantly. [14] Exercise is adjunctive, not a replacement for hormonal therapy in women with moderate to severe VMS.

Practical Protocol Overview for a Woman at Barrymore's Stage

A board-certified menopause specialist evaluating a 49 to 50-year-old woman with irregular cycles, moderate VMS, mood disruption, and confirmed perimenopausal FSH levels might reasonably initiate the following (all prescription-only, requiring individual physician assessment):

Estrogen: Transdermal estradiol 0.05 mg/day (e.g., Climara patch, changed weekly) or equivalent daily estradiol gel 0.75 mg.

Progesterone: Oral micronized progesterone (Prometrium) 200 mg nightly for days 1 through 12 of each calendar month (sequential), transitioning to 100 mg continuous once menopause is confirmed.

Testosterone (if indicated by symptoms and labs): Off-label compounded testosterone cream 0.5 to 1 mg/day transdermal, targeting serum total testosterone of 15 to 70 ng/dL, per Endocrine Society guidance. [9]

Follow-up: Serum estradiol, FSH, and testosterone at 6 to 8 weeks, endometrial monitoring by transvaginal ultrasound if any abnormal bleeding occurs, and annual clinical review.

This is a general educational protocol reflecting current guideline consensus. No specific protocol for Drew Barrymore is known to this publication. Individual prescribing decisions require a licensed clinician.

Access and Cost Considerations

FDA-approved transdermal estradiol patches (generic) cost roughly $30 to $60 per month with insurance or discount cards. Generic oral micronized progesterone 200 mg runs approximately $40 to $80 per month. Compounded testosterone for women typically costs $30 to $70 per month through a compounding pharmacy.

Telehealth menopause platforms have expanded access significantly since 2020. The American College of Obstetricians and Gynecologists (ACOG) released a 2022 committee opinion supporting telehealth-delivered menopause care as equivalent to in-person care for most non-surgical hormone management decisions. [15]